News

Revenue up 6.8% to RMB5.0 billion, with international expansion and hotel management driving strong momentum.

TEM raises its 2026 revenue outlook as oncology testing, data demand and FDA-linked pricing gains support growth and cash flow improvement.

Tempus AI (NASDAQ:TEM) reported second-quarter revenue growth of 22% and raised its full-year outlook, citing accelerating oncology testing volumes, expanding demand for its data and artificial intelligence offerings, and expected reimbursement benefits from newly approved diagnostic products. Reve

Tempus AI Inc (TEM) reports strong Q2 2026 results with record revenue, FDA approval for xT CDx, and a major BioNTech partnership, driving a raised outlook for 25% annual growth.

While the top- and bottom-line numbers for Tempus (TEM) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Tempus (TEM) delivered earnings and revenue surprises of +69.23% and +0.40%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

TEM heads into Q2 earnings with 21.3% expected revenue growth, strong diagnostics demand and AI deals, but near-term margin pressure remains.

Tempus (TEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tempus (TEM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Tempus AI (NASDAQ:TEM) reported first-quarter 2026 revenue of $348.1 million, up a little over 36% year over year, as the company posted growth across both its diagnostics and data and applications segments and raised its full-year outlook. Founder and CEO Eric Lefkofsky said diagnostics revenue ca

Moby summary of Tempus AI, Inc.'s Q1 2026 earnings call

Tempus (TEM) delivered earnings and revenue surprises of +38.10% and +0.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Fulgent Genetics (FLGT) delivered earnings and revenue surprises of -89.47% and +4.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

TruBridge (TBRG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TEM faces pressure ahead of Q1 earnings as macro headwinds, high valuation and estimate trends cloud its near-term investment appeal.